Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an announcement.
Lepu Biopharma Co., Ltd. announced a positive profit alert, expecting a profit of not less than RMB24 million for the first half of 2025, marking a significant turnaround from a loss of approximately RMB197.0 million in the same period of 2024. This improvement is attributed to substantial revenue growth driven by increased sales of PUYOUHENG and income from a licensing collaboration with ArriVent BioPharma, Inc. The announcement indicates a strong operational performance and potential positive implications for stakeholders, although the results are preliminary and subject to finalization.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, with notable products including PUYOUHENG (Pucotenlimab Injection) and a licensing collaboration for MRG007 with ArriVent BioPharma, Inc.
Average Trading Volume: 29,539,096
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.78B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.